2020
-
Erlandson KM, Bradford Y, Samuels DC, Brown TT, Sun J, Wu K, Tassiopoulos K, Ritchie MD, Haas DW, Hulgan T. Mitochondrial DNA Haplogroups and Frailty in Adults Living with HIV. AIDS research and human retroviruses. 2020 Dec;36(36). 214-219.
-
Macatangay BJC, Gandhi RT, Jones RB, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR. T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS (London, England). 2020 Dec 1;34(34). 15-24. NIHMSID: NIHMS1556319.
-
Gandhi RT, Cyktor JC, Bosch RJ, Mar H, Laird GM, Martin A, Collier AC, Riddler SA, Macatangay BJ, Rinaldo CR, Eron JJ, Siliciano JD, McMahon DK, Mellors JW. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. The Journal of infectious diseases. 2020 Aug 21.
-
Overton ET, Kantor A, Fitch KV, Muntner P, Supparatpinyo K, Mosepele M, Mohapi L, Cardoso SW, Patil S, De Lacerda MVG, McComsey G, Aberg JA, Douglas PS, Grinspoon SK, Ribaudo H, Wyatt CM. An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. The Journal of infectious diseases. 2020 Jul 9;222(222). S41-S51.
-
Umbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. The Journal of infectious diseases. 2020 Jul 9;222(222). S52-S62.
-
Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. The Journal of infectious diseases. 2020 Jul 9;222(222). S8-S19.
-
Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. The Journal of infectious diseases. 2020 Jul 9;222(222). S31-S40.
-
Zanni MV, Currier JS, Kantor A, Smeaton L, Rivard C, Taron J, Burdo TH, Badal-Faesen S, Lalloo UG, Pinto JA, Samaneka W, Valencia J, Klingman K, Allston-Smith B, Cooper-Arnold K, Desvigne-Nickens P, Lu MT, Fitch KV, Hoffman U, Grinspoon SK, Douglas PS, Looby SE. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. The Journal of infectious diseases. 2020 Jul 9;222(222). S20-S30.
-
Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. The Journal of infectious diseases. 2020 Jul 9;222(222). S63-S69.
-
Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, Godfrey C, Eron JJ, McMahon DK, Mellors JW, Gandhi RT. Male sex and obesity are associated with residual plasma HIV-1 viremia in persons on long-term antiretroviral therapy. The Journal of infectious diseases. 2020 Jun 30.
-
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, McComsey GA, Palella FJ, Tassiopoulos K, Erlandson KM. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Feb 26.
-
Chow FC, Lyass A, Mahoney TF, Massaro JM, Triant VA, Wu K, Berzins B, Robertson K, Ellis RJ, Tassiopoulos K, Taiwo B, D'Agostino RB. Baseline 10-year cardiovascular risk scores predict cognitive function in older persons, and particularly women, living with HIV infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Jan 3.
2019
-
Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. The Journal of clinical investigation. 2019 Dec 15;129(129). 3339-3346.
-
Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT. Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses. Journal of acquired immune deficiency syndromes (1999). 2019 Dec 15;81(81). 594-599. NIHMSID: NIHMS1526923.
-
Mathur S, Roberts-Toler C, Tassiopoulos K, Goodkin K, McLaughlin M, Bares S, Koletar SL, Erlandson KM. Detrimental Effects of Psychotropic Medications Differ by Sex in Aging People With HIV. Journal of acquired immune deficiency syndromes (1999). 2019 Dec 1;82(82). 88-95. NIHMSID: NIHMS1528419.
-
Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, Tebas P, Gandhi RT. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. Journal of acquired immune deficiency syndromes (1999). 2019 Dec 1;82(82). e27-e31. NIHMSID: NIHMS1531940.
-
Gillman J, Janulis P, Gulick R, Wallis CL, Berzins B, Bedimo R, Smith K, Aboud M, Taiwo B. Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. The Journal of antimicrobial chemotherapy. 2019 Dec 1;74(74). 2365-2369.
-
Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA The Journal of antimicrobial chemotherapy. 2019 Dec 1;74(74). 1376-1380.
-
Fida M, Rizza SA, Temesgen Z. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy. Drugs of today (Barcelona, Spain : 1998). 2019 May;55(55). 297-304.
-
Masters MC, Perez J, Tassiopoulos K, Andrade A, Ellis R, Yang J, Brown TT, Palella FJ, Erlandson KM. Gait Speed Decline Is Associated with Hemoglobin A1C, Neurocognitive Impairment, and Black Race in Persons with HIV. AIDS research and human retroviruses. 35(35). 1065-1073.
2018
-
Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK. Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. The Journal of infectious diseases. 2018 Dec 20;218(218). 234-238.
-
Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Dec 17;66(66). 1689-1697.
-
Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenetics and genomics. 2018 Dec;28(28). 179-187. NIHMSID: NIHMS969312.
-
Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW. Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open forum infectious diseases. 2018 Oct;5(5). ofy242.
2017
-
Tassiopoulos K, Abdo M, Wu K, Koletar SL, Palella FJ, Kalayjian R, Taiwo B, Erlandson KM. Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS (London, England). 2017 Dec 23;31(31). 2287-2294. NIHMSID: NIHMS900112.
-
Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. The Journal of infectious diseases. 2017 Dec 1;216(216). 554-564.
-
Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW. Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenetics and genomics. 2017 Dec;27(27). 101-111. NIHMSID: NIHMS834680.
-
Johs NA, Wu K, Tassiopoulos K, Koletar SL, Kalayjian RC, Ellis RJ, Taiwo B, Palella FJ, Erlandson KM. Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jul 1;65(65). 83-91.
-
Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS pathogens. 2017 Apr;13(13). e1006285.
-
Yendewa GA, Salata RA. Hot News: Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017. AIDS reviews. 19(19). 167-172.
2015
-
Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, De Bakker PI, Haas DW, McLaren PJ. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenetics and genomics. 2015 Feb;25(25). 51-9. NIHMSID: NIHMS668995.
2013
-
Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS research and human retroviruses. 2013 Oct;29(29). 1293-9.
2012
-
Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenetics and genomics. 2012 Dec;22(22). 858-67. NIHMSID: NIHMS440610.
2011
-
Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (London, England). 2011 Jan 2;25(25). 37-47. NIHMSID: NIHMS244137.
-
Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 253-64. NIHMSID: NIHMS281119.
2010
-
Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of infectious diseases. 2010 Sep 1;202(202). 717-22. NIHMSID: NIHMS211349.